US Pharm. 2011;36(4):42. 

Pfizer Inc has entered into a series of agreements with Aurobindo Pharma Ltd., based in India, to commercialize medicines that have come off patent and have lost market exclusivity in the U.S. and Europe. Under the agreements, Pfizer acquires the rights to 39 generic solid oral dose products in the U.S. and 20 in Europe, plus an additional 11 in France. These medicines cover a broad range of therapeutic areas including cardiovascular disease and central nervous system disorders.  

The medicines will be commercialized in the U.S. through Pfizer's Greenstone subsidiary. Pfizer has also acquired rights to 12 sterile injectable products, including penicillins and cephalosporins, in the U.S. and Europe. These agreements are an expansion of a five-product U.S. deal that Pfizer and Aurobindo entered into in July 2008.